Remove 2014 Remove Competition Remove Healthcare
article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

But increased competition is on the horizon. Competition starts to heat up. In a case filed in California in 2021, Molina Healthcare claimed Jazz Pharmaceuticals engaged in a “comprehensive anticompetitive scheme to suppress generic competition for Xyrem,” abused the REMS program, and “engaged in sham patent litigation.”.

article thumbnail

How Value Based Health Care Will Impact Medical Sales

Spotio

The move from fee-for-service to value-based reimbursement is a sea change for the healthcare industry. The goals are to increase quality, decrease costs and turn health care into a competitive marketplace. They cite a 24% increase in drug costs per hospital admission in 2014 and a 12% increase in 2015.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Biogen’s $900 million settlement signals scrutiny on speaker fees

Pharmaceutical Technology

In 2009, former Biogen employee Michael Bawduniak filed a lawsuit claiming that Biogen had violated the False Claims Act and the Anti-Kickback Statute by providing millions of dollars to healthcare providers (HCPs) as an incentive to prescribe three of its multiple sclerosis (MS) drugs. BIIB107 is a monoclonal antibody that targets ?4

article thumbnail

Cutting the combination therapy access issue down to size

pharmaphorum

The consequences of this – for individual patients, healthcare systems, innovation, and the wider R&D community – are as obvious as they are far reaching, she goes on. This access conundrum was acknowledged by NICE as far back as 2014, and has been sitting in pharma’s “inbox” for some time. Too hard to fix?

article thumbnail

Interchangeability of biosimilars in the EU – the industry impact

European Pharmaceutical Review

She has experience on issues arising during the lifecycle of medicinal products, including optimisation of IP regulatory rights, advertising, product liability, competition and market access issues. Chris was named a ‘Rising Star’ in the 2022 Legal 500 Rankings for Life Sciences and Healthcare. Directive 2001/83 (as amended).

article thumbnail

What factors are driving life sciences FDI in 2022?

Pharmaceutical Technology

Linked to talent, the presence of good universities is another great sign for life sciences, especially institutions with a focus on healthcare. Real estate options, schools, recreational and cultural amenities, healthcare systems, cost of living, transportation, crime and climate are all key considerations.

article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

The healthcare industry is successful in innovating new treatment paradigms ranging from small molecular to biological therapeutics to personalised medicines. The lengthy validation of defossilised organic chemicals and plastics for the healthcare sector will take several years. The path to real zero.